Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)

NCT05110976 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05110976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05110976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 16, 2021
Completion date
August 2, 2023
Enrollment
170 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

asthma